25. January 2018

More and more of the new OSD drugs comprise of highly active components, where just milligrams of API are required for one daily medical dose. Thus, the pharmaceutical industry is facing increasing demand from regulatory authorities to achieve lower limits with regards to cross contamination. On the other side, rising HSE requirements come up, in order to avoid negative health effects to the personnel producing those medicines.